

Pharma has challenges. Xylem has new solutions.



Global Pharma Water CapEx is exploding at \$22B+¹

You need to ensure your future investment in pharma water solutions preserves this precious resource efficiently.

New drug approval takes up to \$2.4B²

Your water solution investments need improved processes and efficiency to get you to market faster.




MemGEN™ Water Generation Solution

Xylem delivers the efficiency and value your investment demands.

The new **MemGEN** water generation solution features a pre-engineered, scalable design with lifetime customer support for enhanced value and efficiency.

Xylem support and expertise reduce the risk of costly downtime.

Xylem's industry-leading service and available 24/7 remote monitoring with predictive analytics improves uptime and ensures operating reliability.



Xylem delivers end-to-end time, cost, and resource savings.

The **MemGEN** solution accelerates speed to market with streamlined design, quoting, delivery, and installation, and provides lifecycle energy & water savings.

Xylem experts understand global regulatory compliance.

The **MemGEN** system is designed to facilitate compliance with Global Pharmacopeia Standards for PW and WFI. Xylem provides comprehensive support and documentation to keep you audit-ready.



At \$100K to \$500K per hour, downtime is costly³

You need to maximize uptime to increase profitability.

It can take up to 15 years to obtain regulatory approval⁴

You need to establish and maintain operational compliance while being audit-ready to avoid delays in approval.



Innovation to keep you growing.

The MemGEN water generation solution provides you with advanced efficiency and increasing value throughout its lifecycle.



Faster design, delivery, installation, and setup



Industry-leading service and support from proposal to operation and maintenance



Operational efficiency and enhanced uptime



Regulatory compliance and audit support

Learn more at xylem.com/memgen

SOURCES: (1) GWI, 2025, (2) Scientific American, (3) Denison Technologies, (4) Cancer Research UK

xylem